FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.
You may also be interested in...
Doctors Urge Caution In Interpreting FDA’s SGLT2 Warning
Endocrinologists raise concerns over FDA case reports because diabetic ketoacidosis may be a risk for type 1 diabetes patients taking SGLT2 inhibitors, but it is very rare in type 2 diabetes.
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
In an age of diabetes drug safety scares, will patients turn off of the thiazolidinedeione class altogether, or will the warning go unnoticed?